ACMG updated recommendations a positive for Natera, Myriad, says Stephens

Stephens analyst Mason Carrico views updated recommendations around non-invasive prenatal screening from the American College of Medical Genetics and Genomics as a positive for Natera (NTRA) and Myriad Genetics (MYGN). The analyst believes the updated recommendations could improve access for patients and provide incremental tailwinds for broader NIPS adoption. While Carrico continues to view ACOG guideline inclusion as the key catalyst to drive coverage of microdeletions, the ACMG recommendation could be viewed as a potential positive indicator. The analyst maintains an Overweight rating on Natera and Equal Weight rating on Myriad.